These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33627051)

  • 41. Ethnic differences in COVID-19 mortality in the second and third waves of the pandemic in England during the vaccine rollout: a retrospective, population-based cohort study.
    Bosworth ML; Ahmed T; Larsen T; Lorenzi L; Morgan J; Ali R; Goldblatt P; Islam N; Khunti K; Raleigh V; Ayoubkhani D; Bannister N; Glickman M; Nafilyan V
    BMC Med; 2023 Jan; 21(1):13. PubMed ID: 36617562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COVID-19 vaccination during pregnancy: coverage and safety.
    Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
    Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Researchers Strive to Recruit Hard-Hit Minorities Into COVID-19 Vaccine Trials.
    Jaklevic MC
    JAMA; 2020 Sep; 324(9):826-828. PubMed ID: 32789501
    [No Abstract]   [Full Text] [Related]  

  • 46. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.
    Checcucci E; Piramide F; Pecoraro A; Amparore D; Campi R; Fiori C; Elhage O; Kotecha P; Vyakarnam A; Serni S; Dasgupta P; Porpiglia F
    Panminerva Med; 2022 Mar; 64(1):72-79. PubMed ID: 32456404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Facilitators and barriers to COVID-19 vaccination uptake among ethnic minorities: A qualitative study in primary care.
    Magee L; Knights F; Mckechnie DGJ; Al-Bedaery R; Razai MS
    PLoS One; 2022; 17(7):e0270504. PubMed ID: 35802738
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The mediating effect of health literacy on COVID-19 vaccine confidence among a diverse sample of urban adults in Boston and Chicago.
    Hurstak EE; Paasche-Orlow MK; Hahn EA; Henault LE; Taddeo MA; Moreno PI; Weaver C; Marquez M; Serrano E; Thomas J; Griffith JW
    Vaccine; 2023 Apr; 41(15):2562-2571. PubMed ID: 36907736
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: self-controlled case series study.
    Hippisley-Cox J; Patone M; Mei XW; Saatci D; Dixon S; Khunti K; Zaccardi F; Watkinson P; Shankar-Hari M; Doidge J; Harrison DA; Griffin SJ; Sheikh A; Coupland CAC
    BMJ; 2021 Aug; 374():n1931. PubMed ID: 34446426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancing Public Health Communication Regarding Vaccine Trials: Design and Development of the Pan-European VACCELERATE Toolkit.
    Argyropoulos CD; Leckler J; Salmanton-García J; Constantinou M; Alexandrou A; Themistocleous S; Noula E; Shiamakkides G; Nearchou A; Stewart FA; Albus K; Koniordou M; Kopsidas I; Spivak O; Hellemans M; Hendrickx G; Davis RJ; Azzini AM; Simon PV; Carcas-Sansuan AJ; Askling HH; Vene S; Prellezo JB; Álvarez-Barco E; Macken AJ; Di Marzo R; Luís C; Olesen OF; Frias Iniesta JA; Barta I; Tóth K; Akova M; Bonten MMJ; Cohen-Kandli M; Cox RJ; Součková L; Husa P; Jancoriene L; Launay O; Lundgren J; Mallon P; Armeftis C; Marques L; Naucler P; Ochando J; Tacconelli E; van Damme P; Zaoutis T; Hofstraat S; Bruijning-Verhagen P; Zeitlinger M; Cornely OA; Pana ZD
    JMIR Public Health Surveill; 2023 Apr; 9():e44491. PubMed ID: 36878478
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.
    Menni C; Klaser K; May A; Polidori L; Capdevila J; Louca P; Sudre CH; Nguyen LH; Drew DA; Merino J; Hu C; Selvachandran S; Antonelli M; Murray B; Canas LS; Molteni E; Graham MS; Modat M; Joshi AD; Mangino M; Hammers A; Goodman AL; Chan AT; Wolf J; Steves CJ; Valdes AM; Ourselin S; Spector TD
    Lancet Infect Dis; 2021 Jul; 21(7):939-949. PubMed ID: 33930320
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Black and Minority Ethnic (BAME) Alliance Against COVID-19: One Step Forward.
    Ahmed MH
    J Racial Ethn Health Disparities; 2020 Oct; 7(5):822-828. PubMed ID: 32789564
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    Whiteley WN; Ip S; Cooper JA; Bolton T; Keene S; Walker V; Denholm R; Akbari A; Omigie E; Hollings S; Di Angelantonio E; Denaxas S; Wood A; Sterne JAC; Sudlow C;
    PLoS Med; 2022 Feb; 19(2):e1003926. PubMed ID: 35192597
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California.
    Carson SL; Casillas A; Castellon-Lopez Y; Mansfield LN; Morris D; Barron J; Ntekume E; Landovitz R; Vassar SD; Norris KC; Dubinett SM; Garrison NA; Brown AF
    JAMA Netw Open; 2021 Sep; 4(9):e2127582. PubMed ID: 34591103
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.
    Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC
    Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.